Leveraging bacteria for cancer immunotherapy has gradually attracted wide attention since the discovery of“Cloey’s toxin.”However,one of the persistent challenges for bacteria-based therapy is striking a balance be...Leveraging bacteria for cancer immunotherapy has gradually attracted wide attention since the discovery of“Cloey’s toxin.”However,one of the persistent challenges for bacteria-based therapy is striking a balance between safety and immunogenicity.Genetically engineered bacteria with virulence factors removed could further enhance antitumor ability by integrating genetic elements.In addition,bacterial derivatives,including outer membrane vesicles(OMVs)produced by bacterial secretion and nanovesicles synthesized by modification of OMVs,could enhance antitumor immunity while improving safety.This perspective discusses the unique advantages of engineered bacteria and their derivatives for immunotherapy,as well as the challenges that need to be overcome to achieve clinical translation.展开更多
基金supported by the National Natural Science Foundation of China(nos.82222035 and 82372106)the Shenzhen Medical Research Found(no.B2302041).
文摘Leveraging bacteria for cancer immunotherapy has gradually attracted wide attention since the discovery of“Cloey’s toxin.”However,one of the persistent challenges for bacteria-based therapy is striking a balance between safety and immunogenicity.Genetically engineered bacteria with virulence factors removed could further enhance antitumor ability by integrating genetic elements.In addition,bacterial derivatives,including outer membrane vesicles(OMVs)produced by bacterial secretion and nanovesicles synthesized by modification of OMVs,could enhance antitumor immunity while improving safety.This perspective discusses the unique advantages of engineered bacteria and their derivatives for immunotherapy,as well as the challenges that need to be overcome to achieve clinical translation.
